Gedea Biotech awarded SEK 3M from SWElife and MedTech4Health for groundbreaking antibiotic free women’s health trial - Gedea Biotech
Summary
Impact on microbiome could be key to preventing vulvovaginal infection recurrenceLund, Sweden, April 4, 2023: Gedea Biotech today announced it has been awarded SEK 3M grant from the Swedish innovation programs, SWElife and MedTech4Health in a collaboration with Danderyd hospital, Huddinge hospital and Karolinska Institute, to fund a further clinical trial of its antibiotic free treatment pHyph for the treatment of vulvovaginal candida infections (VVC).Vaginal infections affect at least 400 million women worldwide every year, but with current treatments, the risk of recurrence is substantial as antimicrobial resistance also rapidly increases. "We are delighted to receive this grant from SWElife and MedTech4Health, an investment that is particularly welcome given that womens health is a neglected area," says Annette S\xe4fholm, CEO of Gedea Biotech. "The study, which aims to confirm the safety and efficacy of pHyph in the treatment of vulvovaginal candidiasis (VVC), also focuses on analyzing how the vaginal microbiome - believed to play a key role in preventing recurrence - is affected by the treatment".For further information, please contact: Annette S\xe4fholm, CEO Gedea Biotech Telephone: +46 708 - 91 86 81 Email: This email address is being protected from spambots. In collaboration with patients, healthcare, academia, and business, we contribute to increasing value for people affected by disease in their everyday lives. We support collaboration within academia, industry, and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.